My watch list  


News Gleevec

  • Novartis settles patent litigation on Gleevec with Sun Pharma subsidiary

    Novartis Pharmaceuticals Corporation has settled its litigation with the United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec® (imatinib mesylate), which expire in 2019 (including pediatric exclusivity). more

  • Laboratory detective work points to potential therapy for cancer

    University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks. By screening a library of FDA-approved anticancer drugs that previously wouldn't have been considered as a treatment for a rare type of cancer, UPCI scientists were surprised when th more

  • Interaction between two leukemia drugs explained

    Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications. Prof. Stephan Grzesiek’s group at the Biozentrum of the University of Basel, in collaboration with Dr. Wolfgang Jahnk more

All news on gleevec

Publications Gleevec

All publications on gleevec


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE